ReviewJBRA assisted reproduction2026
Global Research Trends in Immunotherapies for Recurrent Pregnancy Loss: A Bibliometric Analysis.
Review in JBRA assisted reproduction, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This bibliometric study investigates global research trends in the application of immunotherapies for managing recurrent pregnancy loss (RPL). Data were retrieved from the Web of Science (WoS) database, encompassing 1,735 publications from 1964 to 2024. The analysis demonstrates a steady increase in research activity, with an average annual growth rate of 1.14%. Leading journals in the field include The American Journal of Reproductive Immunology and Human Reproduction, while prominent contributors such as Ole Bjarne Christiansen and William H. Kutteh have significantly influenced the domain. The United States, China, and the United Kingdom were identified as the most productive countries in terms of publication volume and citation metrics. Keyword co-occurrence analysis reveals a thematic progression from early-stage experimental treatments to a more advanced focus on immunological and molecular mechanisms underlying RPL. Among various therapeutic modalities, heparin, aspirin, and intravenous immunoglobulin have been the most frequently studied. Meanwhile, novel immunotherapies are emerging as promising alternatives, although their clinical efficacy remains to be thoroughly validated. This study emphasizes the critical role of international collaboration in advancing the field and highlights persistent research gaps that warrant further investigation. Overall, the findings provide a comprehensive overview of the evolution, current status, and future directions of immunotherapy research in the context of recurrent pregnancy loss..
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.